- Home
- DAVA vs PRQR Comparison
DAVA vs PRQR Comparison
Compare DAVA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | PRQR |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.2M | 166.5M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DAVA | PRQR |
|---|---|---|
| Price | $2.88 | $1.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $13.50 | $7.25 |
| AVG Volume (30 Days) | 451.0K | ★ 554.2K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.07 | $13.92 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $1.33 |
| 52 Week High | $16.05 | $3.10 |
Technical Indicators
Market Signals| Indicator | DAVA | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 50.52 |
| Support Level | N/A | $1.51 |
| Resistance Level | $3.58 | $1.58 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 24.78 | 67.27 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.